Position Summary
The Therapy Development Manager (TDM) is responsible for all commercial and therapy
development activities of the Paradise uRDN system in the defined territory or region. This team member develops and executes strategies and tactics to successfully establish the Recor and Paradise brand and drives uRDN therapy awareness and adoption in selected target key centers (CoE) and referral sites aiming to establish Recor & Paradise as THE leading company and brand in the market.
Working in close collaboration with all internal departments like therapy development/marketing,
training & education, clinical affairs, scientific affairs or market access is essential for success.
The position will report to the Senior Director of Commercial and Therapy Development EMEA.
About us
Recor Medical Ltd. / Recor Medical Europe GmbH, headquartered in Palo Alto, CA, is an innovative medical technology company focused on transforming the management of hypertension, the leading cardiovascular risk factor in the world. Recor has pioneered the innovative, minimally invasive use of ultrasound in renal denervation to lower blood pressure in patients with hypertension. The company is focused on investing in high quality product development efforts, as well as rigorous clinical studies to create a strong foundation for future clinical adoption.
Recor Medical is a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd. Otsuka Medical Devices focuses on the global development and commercialization of endovascular therapies that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical treatment. Otsuka Medical Devices Co., Ltd. is a subsidiary of Otsuka Holdings Co., Ltd., a leading global healthcare group listed on the Tokyo Stock Exchange (JP 4578). With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of approximately US$13 billion in the fiscal year ending December 2021 and has a market capitalization of app. US$19 billion.
Recor Medical EMEA http://www.otsuka.com/en/